Switch to:

GuruFocus Financial Strength Rank measures how strong a company’s financial situation is. It is based on these factors

1. The debt burden that the company has as measured by its Interest coverage (current year).
2. Debt to revenue ratio. The lower, the better
3. Altman Z-score.

A company ranks high with financial strength is likely to withstand any business slowdowns and recessions.

Financial Strength : 8/10

vs
industry
vs
history
Cash to Debt 1.00
CELG's Cash to Debt is ranked higher than
55% of the 1248 Companies
in the Global Biotechnology industry.

( Industry Median: 67.35 vs. CELG: 1.00 )
CELG' s 10-Year Cash to Debt Range
Min: 0.03   Max: No Debt
Current: 1

Equity to Asset 0.35
CELG's Equity to Asset is ranked higher than
56% of the 928 Companies
in the Global Biotechnology industry.

( Industry Median: 0.67 vs. CELG: 0.35 )
CELG' s 10-Year Equity to Asset Range
Min: -0.68   Max: 0.92
Current: 0.35

-0.68
0.92
Interest Coverage 19.75
CELG's Interest Coverage is ranked higher than
53% of the 577 Companies
in the Global Biotechnology industry.

( Industry Median: 10000.00 vs. CELG: 19.75 )
CELG' s 10-Year Interest Coverage Range
Min: 4.47   Max: 9999.99
Current: 19.75

4.47
9999.99
F-Score: 7
Z-Score: 7.17
M-Score: -2.71
GuruFocus Profitability Rank ranks how profitable a company is and how likely the company’s business will stay that way. It is based on these factors:

1. Operating Margin
2. Trend of the Operating Margin (5-year average). The company with an uptrend profit margin has a higher rank.
••3. Consistency of the profitability
4. Piotroski F-Score
5. Predictability Rank•

The maximum rank is 10. A rank of 7 or higher means a higher profitability and may stay that way. A rank of 3 or lower indicates that the company has had trouble to make a profit.

Profitability Rank is not directly related to the Financial Strength Rank. But if a company is consistently profitable, its financial strength will be stronger.

Profitability & Growth : 7/10

vs
industry
vs
history
Operating margin (%) 28.51
CELG's Operating margin (%) is ranked higher than
95% of the 1027 Companies
in the Global Biotechnology industry.

( Industry Median: -78.88 vs. CELG: 28.51 )
CELG' s 10-Year Operating margin (%) Range
Min: -2309.09   Max: 31.71
Current: 28.51

-2309.09
31.71
Net-margin (%) 21.80
CELG's Net-margin (%) is ranked higher than
94% of the 1027 Companies
in the Global Biotechnology industry.

( Industry Median: -78.05 vs. CELG: 21.80 )
CELG' s 10-Year Net-margin (%) Range
Min: -2309.09   Max: 28.88
Current: 21.8

-2309.09
28.88
ROE (%) 30.10
CELG's ROE (%) is ranked higher than
97% of the 1143 Companies
in the Global Biotechnology industry.

( Industry Median: -35.75 vs. CELG: 30.10 )
CELG' s 10-Year ROE (%) Range
Min: -425.42   Max: 25.99
Current: 30.1

-425.42
25.99
ROA (%) 11.16
CELG's ROA (%) is ranked higher than
94% of the 1250 Companies
in the Global Biotechnology industry.

( Industry Median: -28.24 vs. CELG: 11.16 )
CELG' s 10-Year ROA (%) Range
Min: -166.78   Max: 15.8
Current: 11.16

-166.78
15.8
ROC (Joel Greenblatt) (%) 197.96
CELG's ROC (Joel Greenblatt) (%) is ranked higher than
97% of the 1223 Companies
in the Global Biotechnology industry.

( Industry Median: -438.40 vs. CELG: 197.96 )
CELG' s 10-Year ROC (Joel Greenblatt) (%) Range
Min: -1378.72   Max: 191.79
Current: 197.96

-1378.72
191.79
Revenue Growth (3Y)(%) 25.10
CELG's Revenue Growth (3Y)(%) is ranked higher than
92% of the 723 Companies
in the Global Biotechnology industry.

( Industry Median: -2.20 vs. CELG: 25.10 )
CELG' s 10-Year Revenue Growth (3Y)(%) Range
Min: 0   Max: 166.8
Current: 25.1

0
166.8
EBITDA Growth (3Y)(%) 21.90
CELG's EBITDA Growth (3Y)(%) is ranked higher than
92% of the 710 Companies
in the Global Biotechnology industry.

( Industry Median: -5.80 vs. CELG: 21.90 )
CELG' s 10-Year EBITDA Growth (3Y)(%) Range
Min: 0   Max: 75.6
Current: 21.9

0
75.6
EPS Growth (3Y)(%) 21.40
CELG's EPS Growth (3Y)(%) is ranked higher than
90% of the 728 Companies
in the Global Biotechnology industry.

( Industry Median: -7.40 vs. CELG: 21.40 )
CELG' s 10-Year EPS Growth (3Y)(%) Range
Min: -63.2   Max: 118.1
Current: 21.4

-63.2
118.1
» CELG's 10-Y Financials

Financials


Revenue & Net Income
Cash & Debt
Oprt. Cash Flow & Free Cash Flow

» Details

Guru Trades

Q4 2013

CELG Guru Trades in Q4 2013

Chuck Royce 900 sh (New)
Ray Dalio 6,700 sh (New)
Mario Gabelli 11,170 sh (+6.69%)
Ronald Muhlenkamp 147,425 sh (+2.87%)
John Keeley 1,320 sh (unchged)
Pioneer Investments 1,537,450 sh (-0.18%)
RS Investment Management 42,330 sh (-11.3%)
Ken Fisher 2,206 sh (-11.41%)
Jim Simons 1,405,469 sh (-15.72%)
Jeremy Grantham 86,922 sh (-36.84%)
Paul Tudor Jones 2,402 sh (-41.41%)
Louis Moore Bacon 5,000 sh (-75%)
Steven Cohen 18,867 sh (-77.3%)
» More
Q1 2014

CELG Guru Trades in Q1 2014

John Burbank 1,670 sh (New)
Ken Fisher 37,321 sh (+1591.8%)
Ray Dalio 71,200 sh (+962.69%)
Louis Moore Bacon 42,614 sh (+752.28%)
Steven Cohen 71,089 sh (+276.79%)
Paul Tudor Jones 6,686 sh (+178.35%)
Jim Simons 1,606,830 sh (+14.33%)
Ronald Muhlenkamp 149,325 sh (+1.29%)
Pioneer Investments 1,552,050 sh (+0.95%)
John Keeley Sold Out
Mario Gabelli 10,770 sh (-3.58%)
RS Investment Management 40,572 sh (-4.15%)
Chuck Royce 600 sh (-33.33%)
Jeremy Grantham 34,100 sh (-60.77%)
» More
Q2 2014

CELG Guru Trades in Q2 2014

George Soros 688,000 sh (New)
Joel Greenblatt 63,980 sh (New)
Stanley Druckenmiller 276,000 sh (New)
Ken Fisher 131,064 sh (+75.59%)
Mario Gabelli 23,120 sh (+7.34%)
Steven Cohen 204,200 sh (unchged)
Paul Tudor Jones Sold Out
Louis Moore Bacon Sold Out
John Burbank Sold Out
Ray Dalio Sold Out
Chuck Royce Sold Out
Pioneer Investments 3,052,643 sh (-1.66%)
RS Investment Management 75,104 sh (-7.44%)
Jeremy Grantham 50,000 sh (-26.69%)
Ronald Muhlenkamp 144,140 sh (-51.74%)
Jim Simons 495,900 sh (-84.57%)
» More
Q3 2014

CELG Guru Trades in Q3 2014

Louis Moore Bacon 55,000 sh (New)
John Hussman 25,000 sh (New)
Stanley Druckenmiller 560,600 sh (+103.12%)
Ken Fisher 232,137 sh (+77.12%)
RS Investment Management 86,904 sh (+15.71%)
Mario Gabelli 25,760 sh (+11.42%)
Ronald Muhlenkamp 146,940 sh (+1.94%)
Pioneer Investments 3,080,374 sh (+0.91%)
Jeremy Grantham Sold Out
Steven Cohen Sold Out
George Soros Sold Out
Joel Greenblatt Sold Out
Jim Simons 30,400 sh (-93.87%)
» More
» Details

Insider Trades

Latest Guru Trades with CELG

(List those with share number changes of more than 20%, or impact to portfolio more than 0.1%)

GuruDate Trades Impact to Portfolio Price Range * (?) Current Price Change from Average Current Shares
George Soros 2014-09-30 Sold Out 0.45%$83.13 - $96.21 $ 117.1830%0
John Hussman 2014-09-30 New Buy0.2%$83.13 - $96.21 $ 117.1830%25000
Joel Greenblatt 2014-09-30 Sold Out 0.07%$83.13 - $96.21 $ 117.1830%0
Ken Fisher 2014-09-30 Add 77.12%0.02%$83.13 - $96.21 $ 117.1830%232137
Ronald Muhlenkamp 2014-06-30 Reduce -51.74%1.91%$68.45 - $86.8 $ 117.1854%144140
George Soros 2014-06-30 New Buy0.45%$68.45 - $86.8 $ 117.1854%688000
Ray Dalio 2014-06-30 Sold Out 0.08%$68.45 - $86.8 $ 117.1854%0
Joel Greenblatt 2014-06-30 New Buy0.07%$68.45 - $86.8 $ 117.1854%63980
Ken Fisher 2014-06-30 Add 75.59%0.01%$68.45 - $86.8 $ 117.1854%131064
John Burbank 2014-06-30 Sold Out 0.01%$68.45 - $86.8 $ 117.1854%0
Ray Dalio 2014-03-31 Add 962.69%0.07%$69.65 - $85.97 $ 117.1847%142400
John Burbank 2014-03-31 New Buy0.01%$69.65 - $85.97 $ 117.1847%3340
Ken Fisher 2014-03-31 Add 1591.8%0.01%$69.65 - $85.97 $ 117.1847%74642
John Keeley 2014-03-31 Sold Out $69.65 - $85.97 $ 117.1847%0
Ronald Muhlenkamp 2013-12-31 Add 2.87%0.12%$72.25 - $85.39 $ 117.1848%294850
Ray Dalio 2013-12-31 New Buy0.01%$72.25 - $85.39 $ 117.1848%13400
Premium More recent guru trades are included for Premium Members only!!
Premium More recent guru trades are included for USA Subscribe Members only!!
» Interactive Charts

Peter Lynch Chart ( What is Peter Lynch Charts )

Ratios

vs
industry
vs
history
P/E(ttm) 61.40
CELG's P/E(ttm) is ranked higher than
91% of the 1333 Companies
in the Global Biotechnology industry.

( Industry Median: 9999.00 vs. CELG: 61.40 )
CELG' s 10-Year P/E(ttm) Range
Min: 17.91   Max: 618.59
Current: 61.4

17.91
618.59
P/B 16.25
CELG's P/B is ranked higher than
61% of the 1333 Companies
in the Global Biotechnology industry.

( Industry Median: 6.13 vs. CELG: 16.25 )
CELG' s 10-Year P/B Range
Min: 4.02   Max: 23.45
Current: 16.25

4.02
23.45
P/S 13.44
CELG's P/S is ranked higher than
79% of the 1333 Companies
in the Global Biotechnology industry.

( Industry Median: 28.86 vs. CELG: 13.44 )
CELG' s 10-Year P/S Range
Min: 5.37   Max: 28.35
Current: 13.44

5.37
28.35
PFCF 41.41
CELG's PFCF is ranked higher than
95% of the 1333 Companies
in the Global Biotechnology industry.

( Industry Median: 9999.00 vs. CELG: 41.41 )
CELG' s 10-Year PFCF Range
Min: 14.96   Max: 2925.5
Current: 41.41

14.96
2925.5
EV-to-EBIT 44.70
CELG's EV-to-EBIT is ranked higher than
91% of the 1333 Companies
in the Global Biotechnology industry.

( Industry Median: 9999.00 vs. CELG: 44.70 )
CELG' s 10-Year EV-to-EBIT Range
Min: -1411.7   Max: 820.6
Current: 44.7

-1411.7
820.6
PEG 2.77
CELG's PEG is ranked higher than
97% of the 1333 Companies
in the Global Biotechnology industry.

( Industry Median: 9999.00 vs. CELG: 2.77 )
CELG' s 10-Year PEG Range
Min: 1.38   Max: 3.01
Current: 2.77

1.38
3.01
Shiller P/E 85.03
CELG's Shiller P/E is ranked higher than
95% of the 1333 Companies
in the Global Biotechnology industry.

( Industry Median: 9999.00 vs. CELG: 85.03 )
CELG' s 10-Year Shiller P/E Range
Min: 56.57   Max: 2211
Current: 85.03

56.57
2211
Current Ratio 6.32
CELG's Current Ratio is ranked higher than
79% of the 1238 Companies
in the Global Biotechnology industry.

( Industry Median: 4.74 vs. CELG: 6.32 )
CELG' s 10-Year Current Ratio Range
Min: 1.35   Max: 44.53
Current: 6.32

1.35
44.53
Quick Ratio 6.06
CELG's Quick Ratio is ranked higher than
79% of the 1238 Companies
in the Global Biotechnology industry.

( Industry Median: 4.57 vs. CELG: 6.06 )
CELG' s 10-Year Quick Ratio Range
Min: 1.13   Max: 44.15
Current: 6.06

1.13
44.15

Valuation & Return

vs
industry
vs
history
Price/DCF (Projected) 3.61
CELG's Price/DCF (Projected) is ranked higher than
94% of the 1333 Companies
in the Global Biotechnology industry.

( Industry Median: 9999.00 vs. CELG: 3.61 )
CELG' s 10-Year Price/DCF (Projected) Range
Min: 1.66   Max: 122.67
Current: 3.61

1.66
122.67
Price/Median PS Value 1.24
CELG's Price/Median PS Value is ranked higher than
81% of the 1333 Companies
in the Global Biotechnology industry.

( Industry Median: 2.20 vs. CELG: 1.24 )
CELG' s 10-Year Price/Median PS Value Range
Min: 0.48   Max: 7.51
Current: 1.24

0.48
7.51
Price/Peter Lynch Fair Value 3.01
CELG's Price/Peter Lynch Fair Value is ranked higher than
98% of the 1333 Companies
in the Global Biotechnology industry.

( Industry Median: 9999.00 vs. CELG: 3.01 )
CELG' s 10-Year Price/Peter Lynch Fair Value Range
Min: 0.36   Max: 5.1
Current: 3.01

0.36
5.1
Earnings Yield (Greenblatt) 2.20
CELG's Earnings Yield (Greenblatt) is ranked higher than
91% of the 1218 Companies
in the Global Biotechnology industry.

( Industry Median: -6.30 vs. CELG: 2.20 )
CELG' s 10-Year Earnings Yield (Greenblatt) Range
Min: 0.1   Max: 6.6
Current: 2.2

0.1
6.6
Forward Rate of Return (Yacktman) 22.06
CELG's Forward Rate of Return (Yacktman) is ranked higher than
85% of the 162 Companies
in the Global Biotechnology industry.

( Industry Median: 15.36 vs. CELG: 22.06 )
CELG' s 10-Year Forward Rate of Return (Yacktman) Range
Min: -0.6   Max: 34.8
Current: 22.06

-0.6
34.8

Business Description

Industry: Biotechnology » Biotechnology
Compare:NVO, AMGN, GILD, BIIB, CMXHY » details
Traded in other countries:CG3.Germany, CELG.Mexico, CELG.Switzerland,
Celgene Corp is incorporated in Delaware. The Company is an integrated biopharmaceutical company engaged in the discovery, development and commercialization of new therapies designed to treat cancer and immune-inflammatory related diseases. The Company is engaged in new research and development designed to bring new therapies to market and we are involved in research in several scientific areas that may deliver proprietary next-generation therapies, targeting areas including intracellular signaling pathways, protein homeostasis and epigenetics in cancer and immune cells, immunomodulation in cancer and autoimmune diseases and therapeutic application of cell therapies. The Company' commercial stage products include REVLIMID(r), VIDAZA(r), ABRAXANE(r), POMALYST(r)/IMNOVID(r), THALOMID(r) (inclusive of Thalidomide CelgeneTM), ISTODAX(r) and azacitidine for injection (generic version of VIDAZA(r)). The Company faces competition from Amgen, AstraZeneca, Bristol-Myers-Squibb, Eisai, Gilead, Johnson & Johnson, Novartis, Pharmacyclics, Roche/Genentech, Sanofi and Takeda, AbbVie, Amgen, Biogen Idec, Eisai, Johnson & Johnson, Merck, Pfizer and UCB S.A. Regulation by governmental authorities in the United States and other countries is a significant factor in the manufacture and marketing of pharmaceuticals and in its ongoing research and development activities.
» More Articles for CELG

Headlines

Articles On GuruFocus.com
UPDATE: Bionor Pharma Announces That the Combination of Vacc-4x + Revlimid(R) Is Well Tolerated and Nov 18 2014 
Bionor Pharma Announces That the Combination of Vacc-4x + Revlimid(R) Is Safe and Increases CD4 Coun Nov 17 2014 
Three Attractively Priced Small Cap Biotech Stocks Nov 05 2014 
Weekly 52-Week Highs Highlight: ALL, SRE, CLX, CELG Oct 05 2014 
Ken Fisher's Top Increases of the First Quarter Apr 22 2014 
David Winters' 2013 Letter to Wintergreen Fund Shareholders Mar 05 2014 
You Can No Longer Ignore Biotech Feb 07 2014 
Trying to Beat the Market Is a Fool’s Errand Oct 17 2013 
Insiders Are Buying Idera Pharmaceuticals Sep 19 2013 
comment on CELG Mar 20 2013 


More From Other Websites
Celgene: European Decision Not Best Case Scenario, Not Worst Case Either Dec 19 2014
Juno Shares Exploded Post-IPO. Should You Consider Buying Them? Dec 19 2014
Cramer's Mad Dash: Tale of two biotechs Dec 19 2014
European Panel Gives Positive Opinion on Celgene Cancer Drug Dec 19 2014
8:12 am Celgene confirms EMA CHMP adopted a positive opinion for continuous oral treatment with... Dec 19 2014
Celgene Receives Positive CHMP Opinion to Extend REVLIMID® (Lenalidomide) for Continuous Use in... Dec 19 2014
Biotech: More Upside in 2015? Dec 18 2014
Cramer: Here's what the Fed did today Dec 17 2014
Data Presented on REVLIMID® (lenalidomide) Compared with Investigators' Choice in... Dec 16 2014
Results from Phase IIIb Study of POMALYST®/IMNOVID® (pomalidomide) Plus Low-Dose dexamethasone in... Dec 16 2014
Meet 5 Top Biotech Stocks Holding Up In Shaky Market Dec 13 2014
IBD 50: Growth Stocks Fight The Fight In Weak Tape Dec 12 2014
Celgene's Abraxane Succeeds In Early Breast Cancer Dec 11 2014
Cramer: Celgene has phenomenal pipeline Dec 10 2014
Trading Biotechs From His Bedroom Nate Pile Beats The Street Dec 10 2014
Celgene Up on Positive Revlimid Data Presented at ASH Dec 09 2014
Bluebird Bio Stock Spikes On New Blood Treatment Dec 09 2014
Combination of ISTODAX® (romidepsin) and Standard CHOP Demonstrates a Complete Response in 51% of... Dec 09 2014
Cramer: Here's why we're selling off Dec 09 2014
Cramer's Mad Dash: BLUE big winner Dec 09 2014

Personalized Checklist

Checklist has been moved to "Checklist" tab.

Get WordPress Plugins for easy affiliate links on Stock Tickers and Guru Names | Earn affiliate commissions by embedding GuruFocus Charts
GuruFocus Affiliate Program: Earn up to $400 per referral. ( Learn More)
Free 7-day Trial
FEEDBACK